argenx
argenx works on 18 rare diseases tracked on Trial Friend, including Amyotrophic Lateral Sclerosis, Bullous Pemphigoid, Chronic Inflammatory Demyelinating Polyneuropathy and 15 more, with 27 recruiting clinical trials and 2 FDA-approved rare disease drugs.
argenx is a global immunology company headquartered in Belgium, focused on FcRn-blocking antibody therapies for rare autoimmune diseases. Vyvgart (efgartigimod) is FDA-approved for generalized myasthenia gravis (2021) and chronic inflammatory demyelinating polyneuropathy (CIDP, April 2025). Vyvgart Hytrulo, a subcutaneous formulation, is also approved for both indications. The pipeline includes late-stage programs in immune thrombocytopenia, pemphigus, and myositis.
Focus areas at argenx
As a rare disease specialist, argenx has active clinical trial programs and drug development efforts across 18 rare diseases, including Amyotrophic Lateral Sclerosis, Bullous Pemphigoid, Chronic Inflammatory Demyelinating Polyneuropathy, Dermatomyositis, Epidermolysis Bullosa, and 13 additional rare conditions. These programs may span orphan drug designation, novel therapeutic mechanisms, and precision medicine approaches targeting the underlying causes of each disease.
The clinical trials section below shows all active and recruiting studies sponsored by argenx, sourced live from ClinicalTrials.gov. Each trial includes its current recruitment status, study phase (Phase 1 through Phase 4), conditions under investigation, and the number of active trial sites. The FDA-approved drugs section lists treatments that have received U.S. Food and Drug Administration approval, with brand names, generic names, approval dates, and matched rare disease indications from the openFDA database.
argenx is headquartered in Zwijnaarde, Belgium, founded in 2008, publicly traded under the ticker symbol ARGX. The company dedicates its research and development resources exclusively to rare and orphan diseases, working to bring innovative treatments to patients with conditions that have historically had limited or no treatment options.
argenx Drug Pipeline
argenx has 27 active clinical trials across 4 development stages, with 27 currently recruiting participants. Clinical trials advance through phases: Phase 1 tests safety in a small group, Phase 2 evaluates effectiveness and side effects, Phase 3 confirms benefit in a larger population, and Phase 4 monitors long-term safety after FDA approval.
Note: This pipeline includes all of argenx's active interventional trials, not only those targeting rare diseases. We show the full pipeline because a company's broader research activity, therapeutic expertise, and development infrastructure directly shape its ability to advance rare disease programs. A strong overall pipeline often signals deeper clinical operations, faster enrollment capabilities, and greater commitment to bringing new treatments to patients.
argenx Clinical Trials (27)
Active and recruiting clinical trials sponsored by argenx, sourced live from ClinicalTrials.gov. Each trial card shows the study phase, current recruitment status, conditions under investigation, study locations, eligibility criteria, and a direct link to the full ClinicalTrials.gov record. You can also download a one-page PDF summary to share with your doctor.
Note: Recruitment statuses on ClinicalTrials.gov may not immediately reflect recent FDA decisions, sponsor announcements, or enrollment changes. Always confirm a trial's current status directly with the study coordinator.
argenx FDA-Approved Drugs (2)
Medications developed or marketed by argenx that have received U.S. Food and Drug Administration approval. Drug data is sourced from the openFDA database and includes brand names, generic names, approval dates, and matched rare disease indications. Where a drug treats a condition covered by Trial Friend, the disease name links directly to that disease page.
| Drug Name | Brand Name | Rare Diseases | Approval Date |
|---|---|---|---|
| EFGARTIGIMOD ALFA Neonatal Fc Receptor Blocker [EPC] | VYVGART intravenous | Dec 17, 2021 | |
| EFGARTIGIMOD ALFA AND HYALURONIDASE (HUMAN RECOMBINANT) Endoglycosidase [EPC] | VYVGART Hytrulo subcutaneous | Jun 20, 2023 |
argenx Trial Locations
argenx clinical trials are running at 1,509 sites in 59 countries. Click any country to drill down by state, city, and individual research facility. Proximity to a trial site is one of the most important factors in deciding whether to participate.
Rare Disease Focus Areas (18)
Diseases targeted by argenx's clinical trial and drug development programs
Amyotrophic lateral sclerosis is a progressive neurodegenerative disease destroying motor neurons in the brain and spinal cord. This causes progressive weakness and paralysis of voluntary muscles whil...
Bullous pemphigoid is an autoimmune blistering disorder caused by autoantibodies against basement membrane proteins, particularly BP180 and BP230. The condition leads to formation of large fluid-fille...
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is an autoimmune disorder affecting the peripheral nerves, causing progressive weakness and impaired function in the legs and arms. The immune ...
Dermatomyositis is a rare autoimmune inflammatory disease causing muscle weakness and distinctive skin rashes, particularly over joints. It involves inflammation of muscles and skin blood vessels. Abo...
Epidermolysis bullosa is a group of rare genetic blistering disorders caused by mutations affecting proteins anchoring the epidermis to the dermis. Fragile skin blisters and erodes with minimal trauma...
Graves' disease is the most common cause of hyperthyroidism, an autoimmune condition where antibodies stimulate the thyroid gland to produce excessive thyroid hormone. It can cause a wide range of sym...
Patient Resources
Organizations and resources related to argenx's rare disease focus areas
Frequently Asked Questions About argenx
Common questions about argenx's rare disease programs, clinical trials, and treatments.